Showing 4251-4260 of 8827 results for "".
- AD Pipeline Watch: Eblasakimab Monthly Dosing Shows Promise in Phase 2b AD Studyhttps://practicaldermatology.com/news/eblasakimab-monthly-dosing-shows-promise-in-phase-2b-ad-study/2461845/ASLAN Pharmaceuticals’ eblasakimab met the primary endpoint of percent change from baseline in the Eczema Area and Severity Index (EASI) score at week 16 versus placebo in adult patients with moderate-to-severe atopic dermatitis (AD), according to results from the Phase 2b dose-ra
- Novel Peptide T14 May Reflect Age and Photoaging in Human Skinhttps://practicaldermatology.com/news/novel-peptide-t14-may-reflect-age-and-photo-aging-in-human-skin/2461843/A novel peptide ‘T14’ may reflect age and photoaging in human skin, according to a study in Aging. T14 is a 14mer peptide derived from the C-terminus of acetylcholinesterase (AChE). Once cleav
- NY Dermatologist Louise Kaufmann, MD, Wins an International Award for Social Responsibility in Dermatology from L’Oréal and ILDShttps://practicaldermatology.com/news/dr-louise-kaufmann-wins-an-international-awards-for-social-responsibility-in-dermatology-from-loreal-and-ilds/2461842/Louise Kaufmann, MD, a general and cosmetic dermatologist in Great Neck, New York, took home an International Award for Social Responsibility in Dermatology for her efforts to provide access to dermatological care in rural and underserved areas of Jamaica. The awards, sp
- MHRA Grants Marketing Authorization for Incyte's Opzelura Cream for Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescentshttps://practicaldermatology.com/news/mhra-grants-marketing-authorization-for-incytes-opzelura-cream-for-non-segmental-vitiligo-with-facial-involvement-in-adults-and-adolescents/2461838/The Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing clearance for Incyte’s Opzelura (ruxolitinib) cream 15mg/g for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. “Today&rs
- Biosimilar Update: Fresenius Kabi’s Idacio Joins Growing List of Available Humira Biosimilarshttps://practicaldermatology.com/news/biosimilar-update-fresenius-kabis-idacio-joins-growing-list-of-available-humira-biosimilars/2461836/Fresenius Kabi’s citrate-free adalimumab biosimilar
- Biosimilar News: Another Humira Biosimilar Enters US Markethttps://practicaldermatology.com/news/biosimilar-news-another-humira-biosimilar-enters-us-market/2461835/Biocon Biologics Ltd’s HULIO (adalimumab-fkjp) injection, a biosimilar to Humira (adalimumab), is now available in the United States after five years of experience in Europe and two years in Canada. "The launch of HULIO, our biosim
- WCD News: Experts Excited About Ornovi’s Next Generation JAK Inhibitorhttps://practicaldermatology.com/news/wcd-news-experts-excited-about-ornovis-next-generation-jak-inhibitor/2461833/Ornovi's OR-101 is a highly selective next generation JAK3-ITK inhibitor with potentially a better safety profile than JAK inhibitors currently on the market, according to a presentation at the 25th World Congress of Dermatology Meeting 2023 in Singapore. Seemal Desa
- Biosimilar Update: Humira Biosimilar Cyltezo Now Available in U.S.https://practicaldermatology.com/news/biosimilar-update-humira-biosimilar-cyltezo-now-available-in-us/2461831/Boehringer Ingelheim’s Cyltezo (adalimumab-adbm), a U.S. Food and Drug Administration (FDA)-approved Interchangeable biosimilar to Humira (adalimumab), is now commercially available in the U.S. Cyltezo was initially approved as a biosimilar in 2017 for use in multi
- Merz Aesthetics to Distribute AccuVein’s Visualization Systemhttps://practicaldermatology.com/news/merz-aesthetics-to-distribute-accuveins-visualization-system/2461829/Merz Aesthetics is now the sole authorized distributor of AccuVein’s vein visualization system in the U.S. aesthetics market. A limited initial AccuVein field pilot yielded positive results and significant expansion of both new customers and Merz Aesthetics portfolio adoption. Bas
- Dermatology Around the Globe: First JAK for AD Approved in Indiahttps://practicaldermatology.com/news/dermatology-around-the-globe-first-jak-for-ad-approved-in-india/2461828/Intas Pharmaceuticals Ltd launched TOFATAS –a Drugs Controller General of India (DCGI) -approved, Tofacitinib Ointment 2% w/w for the treatment of mild to moderate Atopic Dermatitis (AD) in patients 18 years and above experiencing flare-ups of the disease. "The